Sorry!! The article you are trying to read is not available now.
Aegerion Pharmaceuticals Wins Approval for Cholesterol Drug
MINYANVILLE ORIGINAL Aegerion Pharmaceuticals (NASDAQ:AEGR) has won US approval to sell a drug that treats a rare genetic condition linked to heart disease in young people. Aegerion’s cholesterol-lowering capsule drug Juxtapid was approved by the Food and Drug Administration to help fight homozygous familial hypercholesterolemia. It’s the first drug approved for the money-losing biotech company. The medicine is aimed at a small patient population. Initially Aegerion estimates about 3 000 patients in the US can be treated with the product CEO Marc Beer says. Beer told analysts on a conference call Monday morning that Juxtapid will be priced between ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here